Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. James Gerry Desler FCA | CFO, Company Secretary & Executive Director | 66.45k | -- | 1945 |
| Dr. Mark Eccleston M.B.A., Ph.D. | CEO, Director, Member of Scientific & Commercial Advisory Board | -- | -- | 1971 |
| Mr. Kumar Nawani | Head of Operations | -- | -- | -- |
| Mr. Mark Treharne | Corporate Development Manager | -- | -- | -- |
| Dr. Andrew Carnegie | Head of Strategic Commercial Development | -- | -- | -- |
ValiRx plc
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 16
Description
ValiRx plc, a biopharmaceutical company, engages in the development of oncology therapeutics and companion diagnostics in the United Kingdom. The company develops VAL201, a short peptide that has completed Phase I/II trials for the treatment of prostate cancer; and VAL401, a reformulation of anti-psychotic drug risperidone, which has completed Phase II clinical trial for the treatment of end-stage non-small cell lung cancer. It also develops VAL301, a peptide ingredient that in pre-clinical development for the treatment of endometriosis; BC201, a combination of the peptide ingredient of VAL201/VAL301 with complementary active components for the treatment for patients suffering severe symptoms of Covid-19; and CLX001, a peptide nanoparticle formulation that is in pre-clinical trial for destruction of cancer cells. ValiRx plc was incorporated in 2000 and is based in England, the United Kingdom.
Corporate Governance
Upcoming Events
May 13, 2025 at 10:59 AM UTC - May 19, 2025 at 12:00 PM UTC
ValiRx plc Earnings Date
Recent Events
Recent Events Information Not Available